Brind.

Parabilis Medicines debuted on Nasdaq, achieving IPO haul surpassing Moderna's, while its product received FDA fast-track designation. Regeneron also acquired shares.

1 report, 1 independent Updated Jun 11

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Nasdaq Moderna FDA Regeneron Pharmaceuticals

Keep exploring

The entities involved

Nasdaq
American fully electronic stock exchange
- Apple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Mon 17:22
- Vanguard Short-Term Inflation-Protected Securities ETF is disclosing its holdings to the SEC and trading on the Nasdaq electronic stock exchange.Mon 16:28
Moderna
American biotechnology company
- Analyst downgrades and market challenges are impacting Moderna amid waning demand for COVID-19 vaccines, alongside pipeline successes.Mon 17:09
- Positive test results were reported for Moderna's flu vaccine.Sun 15:33
FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
Regeneron Pharmaceuticals
American pharmaceutical company
- Regeneron Pharmaceuticals and Wave Life Sciences are being compared as healthcare companies.Sun 14:10

Coverage

Newest first; wire copies grouped

Jun 11yahoo.com